Harrow Launches VIGAMOX® in the U.S.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. The U.S. commercial rights to VIGAMOX were purchased by Harrow in January of 2023, and VIGAMOX is the fourt